Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue (2018 - 2025)
Historic Non-Current Deffered Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $1.2 million.
- Adaptive Biotechnologies' Non-Current Deffered Revenue fell 9632.1% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 9632.1%. This contributed to the annual value of $27.3 million for FY2024, which is 3915.12% down from last year.
- According to the latest figures from Q3 2025, Adaptive Biotechnologies' Non-Current Deffered Revenue is $1.2 million, which was down 9632.1% from $20.0 million recorded in Q2 2025.
- Adaptive Biotechnologies' 5-year Non-Current Deffered Revenue high stood at $144.4 million for Q1 2021, and its period low was $1.2 million during Q3 2025.
- In the last 5 years, Adaptive Biotechnologies' Non-Current Deffered Revenue had a median value of $50.9 million in 2023 and averaged $60.1 million.
- As far as peak fluctuations go, Adaptive Biotechnologies' Non-Current Deffered Revenue crashed by 1808.27% in 2024, and later crashed by 9632.1% in 2025.
- Over the past 5 years, Adaptive Biotechnologies' Non-Current Deffered Revenue (Quarter) stood at $98.8 million in 2021, then crashed by 40.66% to $58.6 million in 2022, then decreased by 23.56% to $44.8 million in 2023, then tumbled by 39.15% to $27.3 million in 2024, then crashed by 95.58% to $1.2 million in 2025.
- Its Non-Current Deffered Revenue stands at $1.2 million for Q3 2025, versus $20.0 million for Q2 2025 and $24.8 million for Q1 2025.